Therapeutic Asset Ratings
209 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
tg6050
Non-Small Cell Lung Carcinoma
Transgene
P1
C
(36)
tmt101
Non-Small Cell Lung Carcinoma
Peking Union Medical College Hospital
P1
C
(36)
vet3-tgi
Non-Small Cell Lung Carcinoma
KaliVir Immunotherapeutics
P1
C
(36)
68ganota-anti-mmr-vhh2
Non-Small Cell Lung Carcinoma
Universitair Ziekenhuis Brussel
P2
C
(35)
HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA)
Non-Small Cell Lung Carcinoma
Sanofi
P2
D
(31)
Leucogen
Non-Small Cell Lung Carcinoma
Fudan University
N/A
D
(26)
Mass-dispersesing Decoction
Non-Small Cell Lung Carcinoma
Guangzhou University of Traditional Chinese Medicine
N/A
D
(26)
Teplizumab-MZWV
Non-Small Cell Lung Carcinoma
Grit Biotechnology
N/A
D
(26)
gt201
Non-Small Cell Lung Carcinoma
Grit Biotechnology
N/A
D
(22)
Showing 201 to 209 of 209 assets
Previous
Page 9 of 9
Next
